KOKOKSIB
Jak stosować KOKOKSIB
Tłumaczenie AI
Ta strona ma charakter informacyjny i nie zastępuje konsultacji lekarskiej. Przed zastosowaniem jakiegokolwiek leku skonsultuj się z lekarzem. Jeśli objawy są poważne, skorzystaj z pilnej pomocy medycznej.
Pokaż oryginałTreść ulotki
- INSTRUCTIONS for medical use of the medicinal product TADALAFIL
- Composition
- Pharmaceutical form
- Main physical and chemical properties
- Pharmacotherapeutic group
- Pharmacological properties
- Clinical efficacy and safety
- Clinical characteristics
- Interaction with other medicinal products and other forms of interaction
- Special instructions
- Ability to affect reaction speed when driving vehicles or operating other mechanisms
- Method of administration and dosage
- Overdose
- Adverse reactions
- Shelf life
- Storage conditions
- Packaging
- Release category
- Manufacturer
- Location of the manufacturer and address of the place of business
INSTRUCTIONS for medical use of the medicinal product TADALAFIL
Composition
The active substance: tadalafil; 1 film-coated tablet contains tadalafil 10 mg (mg) or 20 mg (mg); excipients: lactose monohydrate, sodium croscarmellose, microcrystalline cellulose RH102, hydroxypropylcellulose, sodium lauryl sulfate, magnesium stearate, film coating mixture 03K12429: hypromellose 6mPas, titanium dioxide (E 171), talc, triacetin, yellow iron oxide (E 172).
Pharmaceutical form
Film-coated tablets.
Main physical and chemical properties
10 mg: film-coated tablets, from pale yellow to yellow in color, round in shape, biconvex, with engraving “45” on one side and smooth on the other. 20 mg: film-coated tablets, from pale yellow to yellow in color, round in shape, biconvex, with engraving “47” on one side and smooth on the other.
Pharmacotherapeutic group
Drugs for the treatment of erectile dysfunction. ATC code G04B E08.
Pharmacological properties
Pharmacodynamics
Mechanism of action
Tadalafil is a selective reversible inhibitor of cyclic guanosine monophosphate (cGMP) - specific phosphodiesterase type 5 (PDE 5). When sexual stimulation causes local release of nitric oxide, inhibition of PDE 5 by tadalafil produces increased levels of cGMP in the cavernous body. This leads to relaxation of smooth muscles and increased blood flow to the tissues of the penis, thereby creating an erection. Tadalafil does not act without sexual stimulation.
Pharmacokinetics
Absorption. Tadalafil is well absorbed after oral administration. The mean maximum plasma concentration (Cmax) is reached on average 2 hours after administration. The absolute bioavailability of tadalafil after oral administration has not been established.
Clinical efficacy and safety
Three clinical trials were conducted involving 1054 patients to determine the onset of action of tadalafil, which demonstrated statistically significant improvement in erectile function, as well as efficacy over 36 hours and detection of effect as early as 16 minutes after administration compared to placebo.
Clinical characteristics
Indications
For the treatment of erectile dysfunction in adult men. The drug is effective in the presence of sexual stimulation. Tadalafil is not indicated for use in women.
Contraindications
Hypersensitivity to tadalafil or to any other component of the medicinal product.
Interaction with other medicinal products and other forms of interaction
Studies on interactions, the results of which are presented below, were conducted for doses of 10 mg and 20 mg.
Influence of other medicinal products on tadalafil
CYP450 inhibitors. Tadalafil is metabolized mainly by CYP3A4. The selective inhibitor of CYP3A4 - ketoconazole (200 mg daily) - increases the exposure (AUC) of tadalafil (10 mg) by 2 times, and Cmax by 15%.
Special instructions
Before prescribing the medicinal product Tadalafil
Before administering the drug, the doctor should determine the underlying causes of erectile dysfunction and prescribe the appropriate course of treatment.
Cardiovascular system
In the post-marketing period and/or during clinical trials, serious cardiovascular events have been reported, including myocardial infarction, sudden cardiac death, unstable angina, ventricular arrhythmia, cerebrovascular disorders, transient ischemic attack, chest pain, accelerated heart rate, and tachycardia.
Ability to affect reaction speed when driving vehicles or operating other mechanisms
The effect of Tadalafil on the ability to drive vehicles and other mechanisms is minimal.
Method of administration and dosage
For oral administration. The medicinal product should be taken with the recommended content of the active substance.
Adult men
The recommended dose is 10 mg before predicted sexual activity, regardless of food intake.
Overdose
Symptoms. When administered to healthy volunteers in a single dose of tadalafil up to 500 mg and in multiple doses up to 100 mg per day, undesirable effects were similar to those observed with smaller doses of the drug.
Adverse reactions
Undesirable effects most frequently reported during the treatment of erectile dysfunction were headache, dyspepsia, back pain, myalgia, the frequency of which increased with increasing doses of the drug.
| Frequent (≥ 1/100 ≤ 1/10) | Uncommon (≥ 1/1000 ≤ 1/100) | Rare (≥ 1/10000 ≤ 1/1000) | Frequency not known |
|---|---|---|---|
| Disorders of the immune system | |||
| Hypersensitivity reactions | Angioedema2 | ||
| Disorders of the nervous system | |||
| Headache | Dizziness | Cerebrovascular disorders1(including hemorrhagic events), loss of consciousness, transient ischemic attack1, migraine2, seizures2, transient amnesia | |
Shelf life
3 years.
Storage conditions
Store in the original packaging in a place inaccessible to children at a temperature not exceeding 25 °C.
Packaging
For 10 mg: 4 or 7 film-coated tablets in a blister pack. 1 blister pack in a cardboard box.
Release category
By prescription.
Manufacturer
Chilu Pharmaceutical (Hainan) Co., Ltd.
Location of the manufacturer and address of the place of business
No. 273-A, Nanhai Avenue, Neshinl Hi-Tech Zone, Haikou, Hainan 570 314, China.
- Kraj rejestracji
- Postać farmaceutycznatablets, 120 mg
- Kod ATCM01AH05
- Substancja czynna
- Wymaga receptyTak
- Producent
- Te treści mają charakter wyłącznie informacyjny i nie zastępują konsultacji lekarskiej.
- Zamienniki KOKOKSIBPostać farmaceutyczna: tablets, 120 mgSubstancja czynna: etoricoxibWymaga receptyPostać farmaceutyczna: tablets, 30 mg in 7 tablets per blisterSubstancja czynna: etoricoxibWymaga receptyPostać farmaceutyczna: tablets, 60 mg in 7 tablets per blisterSubstancja czynna: etoricoxibWymaga recepty
Odpowiedniki KOKOKSIB w innych krajach
Leki z tą samą substancją czynną dostępne w innych krajach.
Odpowiednik KOKOKSIB w Polska
Lekarze online w sprawie KOKOKSIB
Omów stosowanie KOKOKSIB, bezpieczeństwo i ocenę zasadności recepty zgodnie z obowiązującymi przepisami.
Uzyskaj receptę na KOKOKSIB online
Wypełnij 2-minutowy formularz
Opisz swoje objawy, historię choroby i lek, o który prosisz.
Wybierz lekarza lub pozwól nam przydzielić
Wybierz specjalistę lub dopasujemy Cię do najbliższego dostępnego lekarza.
Lekarz analizuje Twój przypadek
Zazwyczaj w ciągu 30 minut. Może zadawać dodatkowe pytania przez czat.
Odbierz w dowolnej aptece
Recepta elektroniczna wysłana na Twój e-mail — ważna w całej Hiszpanii.
Często zadawane pytania
Bądź na bieżąco z Oladoctor
Informacje o nowych usługach, aktualizacjach produktu i przydatnych materiałach dla pacjentów.